Core Insights - Oramed Pharmaceuticals Inc. is advancing its proprietary oral drug delivery technology through a joint venture named OraTech Pharmaceuticals, Inc. with Hefei Tianhui Biotech Co., Ltd. [4][5] - The joint venture aims to initiate a Phase 3 clinical trial in the U.S. for oral insulin, focusing on key patient subpopulations to demonstrate efficacy [6][11] - HTIT has submitted a Marketing Authorization Application for the oral insulin capsule in China, with commercialization preparations underway [7][11] - Oramed plans to distribute OraTech stock to its shareholders via a dividend, coinciding with OraTech's public trading debut on Nasdaq [8][11] - A cash dividend of approximately $0.25 per share is being evaluated to offset potential tax liabilities related to the OraTech stock distribution [9][11] - Oramed's investment in Scilex Holding Company has generated $70 million from a secured loan agreement, with additional payments expected [12][13] - The company maintains a strong financial position, supported by strategic transactions and disciplined capital allocation [13] - Future growth strategies include pursuing acquisitions and partnerships to leverage technology development [14] Joint Venture and Product Development - The OraTech joint venture combines Oramed's drug delivery technology with HTIT's manufacturing capabilities, aiming to set new standards for oral protein delivery [5][6] - OraTech is expected to receive royalties from sales in China, enhancing its revenue potential [7][11] Financial Strategies - Oramed is working on achieving Nasdaq trading status for OraTech and plans to distribute the majority of its ownership in OraTech to shareholders [8][11] - The company is also exploring cash dividends to enhance shareholder value and mitigate tax concerns [9][11] Strategic Investments - Oramed's investment in Scilex includes a royalty stream from multiple products, with expected royalties of $400,000 for Q4 2024 [12][16] - The company holds a 2% royalty on worldwide sales for ELYXYB and GLOPERBA, with additional profit-sharing arrangements [16]

Core Viewpoint - Scilex Holding Company has made an early installment payment of $13.2 million on its senior secured promissory note to Oramed Pharmaceuticals, with the remaining balance due by March 21, 2025, indicating strong financial management and commitment to debt repayment [1]. Company Overview - Scilex Holding Company is focused on acquiring, developing, and commercializing treatments for obesity, neurodegenerative diseases, cardiometabolic diseases, and non-opioid pain management products for both acute and chronic pain [1][5]. - The company is headquartered in Palo Alto, California [7][10]. Financial Actions - The early payment of $13.2 million reduces the principal balance of the Oramed Note, which will be fully retired by March 21, 2025 [1]. - This financial maneuver reflects the company's strategy to manage its liabilities effectively and enhance its balance sheet [1]. Product Portfolio - Scilex's commercial products include: - ZTlido®: A prescription lidocaine topical product for neuropathic pain relief [5]. - ELYXYB®: An FDA-approved oral solution for acute migraine treatment [5]. - Gloperba®: The first liquid oral version of colchicine for gout flare prophylaxis [5]. - The company has three product candidates in development: - SP-102 (SEMDEXA™): A viscous gel for treating lumbosacral radicular pain, with Phase 3 study completed [6]. - SP-103: A next-generation lidocaine topical system for acute pain, recently completing Phase 2 trials [6]. - SP-104: A low-dose naltrexone hydrochloride for fibromyalgia, with Phase 1 trials completed [6].

Core Insights - Oramed Pharmaceuticals has announced a $20 million stock repurchase program, reflecting confidence in its value and potential [3] - The company is actively pursuing a joint venture with Hefei Tianhui Biotech Co., Ltd. (HTIT) to develop and commercialize oral drug delivery products [6][7] - Oramed is making progress on its Phase 3 oral insulin trial and has engaged with the U.S. FDA to refine its protocol [5] Financial Updates - Oramed has received $40 million out of a total $102 million principal from Scilex Holding Company, with a $20 million installment due in September [4] - The joint venture with HTIT will involve a capital infusion of $70 million from HTIT and $25 million from Oramed [7] Strategic Initiatives - The joint venture aims to leverage HTIT's manufacturing capabilities to support the completion of the Phase 3 trial and the launch of oral insulin sales [7] - Oramed's adaptive strategy for the Phase 3 trial focuses on specific patient subgroups identified as significant responders [5] Company Overview - Oramed Pharmaceuticals specializes in oral drug delivery solutions, particularly for drugs typically administered via injection [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended March 31, 2024 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Em ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Employer | | Incorporation or Organization) | Identification ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended September 30, 2023 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Employer | | Incorporation or Organization) | Identification No.) | | 1185 Avenue of the Amer ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Em ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S. Employer | | Incorporation or Organization) | Identification No.) | | 1185 Avenue of the Americas, Third Floor, New York, NY | 10036 | | (A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35813 ORAMED PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 98-0376008 | | --- | --- | | (State or Other Jurisdiction of | (I.R.S ...